Model RTX-321 - Allogeneic, Off-The-Shelf Artificial Antigen Presenting Cell (aAPC) Therapy Product for R/R HPV 16+ Solid Tumors
From Others
RTX-321 is an allogeneic, off-the-shelf artificial antigen presenting cell (aAPC) therapy product candidate that is engineered to induce a tumor-specific immune response by expanding antigen-specific T cells. RTX-321 expresses hundreds of thousands of copies of an HPV peptide antigen bound to major histocompatibility complex (MHC) class I proteins, the costimulatory molecule 4-1BBL and the cytokine IL-12 on the cell surface to mimic human T cell-APC interactions.
-
Most popular related searches
RTX-321 FOR THE TREATMENT OF HPV 16-POSITIVE CANCERS
STUDY TITLE: Open-label, multicenter, multiple-ascending dose, first-in-human, Phase 1 study of RTX-321 for the treatment of patients that are HLA-A*02:01 positive with persistent, recurrent, or metastatic, unresectable, HPV 16-positive cancers (including cervical cancer, head and neck cancer – including of the nasal and oral cavities, larynx, hypopharynx, nasopharynx, and oropharynx – and anal cancer)
STATUS: RECRUITING
KEY OBJECTIVES
- Safety Assessment
- Pharmacodynamics of RTX-321 will be evaluated through changes in number of CD8+ T-cells in peripheral blood
- Anti-tumor activity of RTX-321 measured by Duration of Response (DoR), Progression Free Survival (PFS), Overall Response Rate (ORR) and Overall Survival (OS)
Customer reviews
No reviews were found for Model RTX-321 - Allogeneic, Off-The-Shelf Artificial Antigen Presenting Cell (aAPC) Therapy Product for R/R HPV 16+ Solid Tumors. Be the first to review!